 | Up a level |
Welte, Tobias, Dellinger, R. Phillip, Ebelt, Henning, Ferrer, Miguel 
ORCID: 0000-0001-8171-6673, Opal, Steven M., Singer, Mervyn ORCID: 0000-0002-1042-6350, Vincent, Jean-Louis ORCID: 0000-0001-6011-6951, Werdan, Karl, Martin-Loeches, Ignacio, Almirall, Jordi ORCID: 0000-0002-3821-4341, Artigas, Antonio, Ignacio Ayestaran, Jose, Nuding, Sebastian, Ferrer, Ricard ORCID: 0000-0002-4859-4747, Sirgo Rodriguez, Gonzalo, Shankar-Hari, Manu ORCID: 0000-0002-5338-2538, Alvarez-Lerma, Francisco, Riessen, Reimer, Sirvent, Josep-Maria, Kluge, Stefan, Zacharowski, Kai ORCID: 0000-0002-0212-9110, Bonastre Mora, Juan, Lapp, Harald, Woebker, Gabriele, Achtzehn, Ute, Brealey, David, Kempa, Axel, Sanchez Garcia, Miguel, Brederlau, Joerg, Kochanek, Matthias, Reschreiter, Henrik Peer, Wise, Matthew P., Belohradsky, Bernd H., Bobenhausen, Iris, Dalken, Benjamin, Dubovy, Patrick, Langohr, Patrick, Mayer, Monika, Schuettrumpf, Joerg, Wartenberg-Demand, Andrea, Wippermann, Ulrike, Wolf, Daniele and Torres, Antoni ORCID: 0000-0002-8643-2167
(2018).
Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study).
Intensive Care Med., 44 (4).
S. 438 - 449.
NEW YORK:
SPRINGER.
ISSN 1432-1238